United Therapeutics (UTHR) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
United Therapeutics (UTHR) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.60 Bn | 42.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.44 Bn | 29.76 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.71 Bn | 17.82 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.64 Bn | 15.25 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 12.03 Bn | 11.50 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.91 Bn | - | - |
| 10 | Alkermes | 8.23 Bn | 7.57 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.59% |
| Mar 31, 2026 | -14.68% |
| Dec 31, 2025 | 20.91% |
| Sep 30, 2025 | 9.58% |
| Jun 30, 2025 | 11.29% |
| Mar 31, 2025 | 5.09% |
| Dec 31, 2024 | 38.78% |
| Sep 30, 2024 | 15.51% |
| Jun 30, 2024 | 7.29% |
| Mar 31, 2024 | 27.27% |
| Dec 31, 2023 | 64.35% |
| Sep 30, 2023 | 11.83% |
| Jun 30, 2023 | 123.45% |
| Mar 31, 2023 | 0.42% |
| Dec 31, 2022 | 17.74% |
| Sep 30, 2022 | 47.08% |
| Jun 30, 2022 | -32.79% |
| Mar 31, 2022 | 747.70% |
| Dec 31, 2021 | 13.56% |
| Sep 30, 2021 | -4.96% |